Lilly acquires AtaiBeckley for up to $3.8 billion, betting on new neuroscience therapies.

```

Psychedelic therapies, which had long existed outside the mainstream pharmaceutical industry, are now seeing accelerated investment from major drug companies. As demand for treatment of mental health disorders such as depression continues to grow and as clinical data improves, this niche sector is beginning to enter the core strategic vision of multinational pharmaceutical companies.

On July 16, it was reported that Eli Lilly announced it would acquire AtaiBeckley for up to $3.8 billion, obtaining the latter’s core psychedelic drug asset BPL-003 for treatment-resistant depression. This is also Eli Lilly's first large-scale move into the field of psychedelic drugs, further strengthening its neuroscience product pipeline.

According to the announcement, Eli Lilly will acquire AtaiBeckley for $6.75 per share in cash, about a 26% premium to Wednesday’s closing price, and will pay up to an additional $2.50 per share upon reaching certain R&D milestones. The total value of this significant transaction amounts to $3.8 billion, including $2.8 billion in upfront cash and an additional $1 billion contingent on future milestones.

Stimulated by the news, AtaiBeckley’s pre-market price rose over 30%, and the company’s stock has nearly doubled in the past year.

Acquisition of Core Asset BPL-003

The core value of this transaction is that Eli Lilly is obtaining AtaiBeckley’s flagship product BPL-003.

BPL-003 is a psychedelic nasal spray for the treatment of treatment-resistant depression. It is currently in late-stage clinical development and has received Breakthrough Therapy designation from the U.S. FDA. Mid-stage clinical data show that patients can experience significant effects as soon as two days after a single administration, with improvement lasting up to around eight weeks.

Compared with similar products, BPL-003’s greatest advantage is that the psychedelic experience lasts only about one to two hours—significantly shorter than the up to eight hours of monitoring required by some competitors—potentially reducing use of medical resources and improving accessibility of treatment.

AtaiBeckley CEO Srinivas Rao previously said the company hopes to build a product that can fit directly into the treatment process of Johnson & Johnson’s Spravato, making it easier for doctors and patients to adopt.

Beyond BPL-003, the company is also developing treatment pipelines for mental disorders such as social anxiety, continuing its deep focus on mental health.

Eli Lilly Continues to Ramp Up Neuroscience

This acquisition is also Eli Lilly’s latest move to strengthen its presence in neuroscience in recent years.

Eli Lilly previously changed the global landscape of depression treatment with its antidepressant Prozac, and in recent years has continued to invest in areas such as Alzheimer’s disease and non-addictive painkillers. According to reports citing insiders, Eli Lilly has long had its eye on the psychedelic track and has been evaluating related acquisition opportunities.

Although weight-loss and diabetes businesses have become Eli Lilly’s most important current growth engines, neuroscience is still considered an essential part of the company’s long-term strategy. This acquisition officially brings psychedelic therapy into Lilly’s own R&D system.

Psychedelic Therapy Moves Toward the Mainstream

Eli Lilly’s entry also reflects how psychedelic therapy is gradually gaining recognition in the mainstream pharmaceutical industry.

In recent years, driven by the commercialization of Johnson & Johnson’s Spravato, ongoing positive clinical research, and improving policy environments, the psychedelic drug market has continued to heat up. Bloomberg Industry Research estimates that by 2032, the global psychedelic therapy market could reach $7 billion.

Major pharmaceutical companies are also ramping up investment. Previously, AbbVie announced an up to $1.2 billion acquisition deal for a depression drug; Definium Therapeutics is advancing LSD-based therapies for major depressive disorder, and GH Research is also developing similar products.

AtaiBeckley was founded by German investor Christian Angermayer, with support from Peter Thiel, and is one of the most high-profile innovative pharmaceutical companies in the field of psychedelic therapy in recent years. With Eli Lilly's entry, this once-niche sector is rapidly entering a phase of fierce competition among major pharmaceutical companies.

Risk Warning and DisclaimerThere are risks in the market, and investment requires caution. This article does not constitute personal investment advice, nor does it take into account the special investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are appropriate for their specific circumstances. If you invest based on this, you do so at your own risk. ```